PET Brain imaging of α7-nAChR with [18F]ASEM

The α7 nicotinic acetylcholine receptor (nAChR) increasingly has been implicated in normal brain physiology, as well as in neuropsychiatric disorders. The α7-nAChR primarily is located in cerebral cortex and sub-cortical regions, compared to the α4β2 nAChR subtype that has a more subcortical distribution. The highly cortical distribution suggests a role of α7-nAChR in cognition. We expanded the first-in-human PET imaging of α7-nAChR with [18F]ASEM from five to 21 healthy non-smoking volunteers and added preliminary evidence of binding in six male patients with schizophrenia. Study aims included 1) confirmation of test-retest reproducibility of [18F]ASEM binding in normal volunteers, 2) demonstration of specificity of [18F]ASEM binding by competition with DMXB-A, an α7-nAChR partial agonist previously tested in clinical trials of patients with schizophrenia, 3) estimation of [18F]ASEM binding potentials and α7-nAChR density in vivo in humans, and 4) α7-nAChR binding in patients with schizophrenia compared to healthy volunteers. Test-retest PET confirmed reproducibility (>90%) (variability ≤ 7%) of [18F]ASEM volume of distribution (VT) estimates in healthy volunteers. Repeated sessions of PET in five healthy subjects included baseline and effect of inhibition after oral administration of 150 mg DMXB-A. From reduction of binding potentials, we estimated the dose-dependent occupancy of α7-nAChR by DMXB-A at 17–49% for plasma concentrations at 60–200 nM DMXB-A. In agreement with evidence post-mortem, α7-nAChR density (Bmax) averaged 0.67–0.82 nM and inhibitor affinity constant (KI) averaged 170–385 nM. Median VT in the six patients with schizophrenia was lower than in healthy volunteers in cingulate cortex, frontal cortex, and hippocampus. Mann-Whitney test identified cingulate cortex and hippocampus as regions with significantly lower median VT in patients than in healthy volunteers when a single outlier patient was excluded from analysis (P = 0.02, corrected for multiple comparisons).

[1]  Ninon Burgos,et al.  New advances in the Clinica software platform for clinical neuroimaging studies , 2019 .

[2]  Dean F. Wong,et al.  The distribution of the alpha7 nicotinic acetylcholine receptor in healthy aging: An in vivo positron emission tomography study with [18F]ASEM , 2018, NeuroImage.

[3]  A. Gjedde,et al.  Radioligand binding analysis of α2 adrenoceptors with [11C]yohimbine in brain in vivo: Extended Inhibition Plot correction for plasma protein binding , 2017, Scientific Reports.

[4]  S. Xie,et al.  Effects of haloperidol, olanzapine, ziprasidone, and PHA‐543613 on spatial learning and memory in the Morris water maze test in naïve and MK‐801‐treated mice , 2017, Brain and behavior.

[5]  M. Bloch,et al.  Alpha-7 nicotinic agonists for cognitive deficits in neuropsychiatric disorders: A translational meta-analysis of rodent and human studies , 2017, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[6]  H. Arias,et al.  3-Furan-2-yl-N-p-tolyl-acrylamide, a positive allosteric modulator of the α7 nicotinic receptor, reverses schizophrenia-like cognitive and social deficits in rats , 2017, Neuropharmacology.

[7]  Richard E. Carson,et al.  PET imaging of α7 nicotinic acetylcholine receptors: a comparative study of [18F]ASEM and [18F]DBT-10 in nonhuman primates, and further evaluation of [18F]ASEM in humans , 2017, European Journal of Nuclear Medicine and Molecular Imaging.

[8]  M. Kassiou,et al.  The Recent Development of α7 Nicotinic Acetylcholine Receptor (nAChR) Ligands as Therapeutic Candidates for the Treatment of Central Nervous System (CNS) Diseases. , 2016, Current pharmaceutical design.

[9]  A. Horti,et al.  Development of [(18)F]ASEM, a specific radiotracer for quantification of the α7-nAChR with positron-emission tomography. , 2015, Biochemical pharmacology.

[10]  G. Knudsen,et al.  Radiosynthesis and in vitro validation of (3)H-NS14492 as a novel high affinity alpha7 nicotinic receptor radioligand. , 2015, European journal of pharmacology.

[11]  M. Kassiou,et al.  The Therapeutic Potential of α7 Nicotinic Acetylcholine Receptor (α7 nAChR) Agonists for the Treatment of the Cognitive Deficits Associated with Schizophrenia , 2015, CNS Drugs.

[12]  Hiroto Kuwabara,et al.  Human Brain Imaging of α7 nAChR with [18F]ASEM: a New PET Radiotracer for Neuropsychiatry and Determination of Drug Occupancy , 2014, Molecular Imaging and Biology.

[13]  R. Papke Merging old and new perspectives on nicotinic acetylcholine receptors. , 2014, Biochemical pharmacology.

[14]  Martin G Pomper,et al.  18F-ASEM, a Radiolabeled Antagonist for Imaging the α7-Nicotinic Acetylcholine Receptor with PET , 2014, The Journal of Nuclear Medicine.

[15]  R. Freedman α7-nicotinic acetylcholine receptor agonists for cognitive enhancement in schizophrenia. , 2014, Annual review of medicine.

[16]  S. Preskorn,et al.  Normalizing Effects of EVP-6124, an Alpha-7 Nicotinic Partial Agonist, on Event-Related Potentials and Cognition: A Proof of Concept, Randomized Trial in Patients with Schizophrenia , 2014, Journal of psychiatric practice.

[17]  M. Geyer,et al.  Evaluating the role of the alpha-7 nicotinic acetylcholine receptor in the pathophysiology and treatment of schizophrenia. , 2013, Biochemical pharmacology.

[18]  A. Horti,et al.  Derivatives of dibenzothiophene for positron emission tomography imaging of α7-nicotinic acetylcholine receptors. , 2013, Journal of medicinal chemistry.

[19]  Anil Kumar,et al.  Characterization of [11C]RO5013853, a novel PET tracer for the glycine transporter type 1 (GlyT1) in humans , 2013, NeuroImage.

[20]  James Robert Brašić,et al.  Glycine Transporter Type 1 Occupancy by Bitopertin: a Positron Emission Tomography Study in Healthy Volunteers , 2013, Neuropsychopharmacology.

[21]  D. Bertrand,et al.  Alpha7 neuronal nicotinic receptors as a drug target in schizophrenia , 2013, Expert opinion on therapeutic targets.

[22]  A. Lira,et al.  Clozapine-Induced Locomotor Suppression is Mediated by 5-HT2A Receptors in the Forebrain , 2012, Neuropsychopharmacology.

[23]  C. Ahnallen,et al.  The role of the &agr;7 nicotinic receptor in cognitive processing of persons with schizophrenia , 2012, Current opinion in psychiatry.

[24]  D. Bertrand,et al.  EVP-6124, a novel and selective α7 nicotinic acetylcholine receptor partial agonist, improves memory performance by potentiating the acetylcholine response of α7 nicotinic acetylcholine receptors , 2012, Neuropharmacology.

[25]  H. Geerts α7 Nicotinic receptor modulators for cognitive deficits in schizophrenia and Alzheimer's disease , 2012, Expert opinion on investigational drugs.

[26]  R. Papke,et al.  Investigation of the Molecular Mechanism of the α7 Nicotinic Acetylcholine Receptor Positive Allosteric Modulator PNU-120596 Provides Evidence for Two Distinct Desensitized States , 2011, Molecular Pharmacology.

[27]  H. Parri,et al.  Research update: Alpha7 nicotinic acetylcholine receptor mechanisms in Alzheimer's disease. , 2011, Biochemical pharmacology.

[28]  G. Knudsen,et al.  11C-NS14492 as a Novel PET Radioligand for Imaging Cerebral α7 Nicotinic Acetylcholine Receptors: In Vivo Evaluation and Drug Occupancy Measurements , 2011, The Journal of Nuclear Medicine.

[29]  Stephen M. Smith,et al.  A Bayesian model of shape and appearance for subcortical brain segmentation , 2011, NeuroImage.

[30]  P. Brust,et al.  Traumatic Brain Injury Elicits Similar Alterations in α7 Nicotinic Receptor Density in Two Different Experimental Models , 2011, NeuroMolecular Medicine.

[31]  M. Bencherif,et al.  Application of Alpha7 Nicotinic Acetylcholine Receptor Agonists in Inflammatory Diseases: An Overview , 2011, Pharmaceutical Research.

[32]  D. Bertrand,et al.  RG3487, a Novel Nicotinic α7 Receptor Partial Agonist, Improves Cognition and Sensorimotor Gating in Rodents , 2011, Journal of Pharmacology and Experimental Therapeutics.

[33]  K. Gross,et al.  Antipsychotic drugs dose-dependently suppress the spontaneous hyperactivity of the chakragati mouse , 2010, Neuroscience.

[34]  L. Price,et al.  Nicotinic acetylcholine receptors and depression: a review of the preclinical and clinical literature , 2010, Psychopharmacology.

[35]  K. Hashimoto,et al.  Preclinical and the first clinical studies on [11C]CHIBA-1001 for mapping α7 nicotinic receptors by positron emission tomography , 2009, Annals of nuclear medicine.

[36]  D. Bertrand,et al.  Nicotinic acetylcholine receptors: an overview on drug discovery , 2009, Expert opinion on therapeutic targets.

[37]  J. Gold,et al.  Initial phase 2 trial of a nicotinic agonist in schizophrenia. , 2008, The American journal of psychiatry.

[38]  Nihal Ahmad,et al.  Dose translation from animal to human studies revisited , 2007, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[39]  C. Gotti,et al.  Neuronal nicotinic receptors: from structure to pathology , 2004, Progress in Neurobiology.

[40]  Karl J. Friston,et al.  Rigid Body Registration , 2003 .

[41]  S. Scheff,et al.  Time-dependent changes in rat brain cholinergic receptor expression after experimental brain injury. , 2002, Journal of neurotrauma.

[42]  D. Woodruff-Pak,et al.  Neuronal nicotinic acetylcholine receptors: involvement in Alzheimer's disease and schizophrenia. , 2002, Behavioral and cognitive neuroscience reviews.

[43]  Mary Johnson,et al.  Laminar distribution of nicotinic receptor subtypes in cortical regions in schizophrenia , 2001, Journal of Chemical Neuroanatomy.

[44]  S. Scheff,et al.  Traumatic brain injury reduces hippocampal alpha7 nicotinic cholinergic receptor binding. , 2000, Journal of neurotrauma.

[45]  William R Kem,et al.  The brain α7 nicotinic receptor may be an important therapeutic target for the treatment of Alzheimer's disease: studies with DMXBA (GTS-21) , 2000, Behavioural Brain Research.

[46]  H. Crawford,et al.  Tobacco affects P50 sensory gating: Auditory event-related potential differences in heavy tobacco smokers and nonsmokers , 2000, NeuroImage.

[47]  R. Kerwin,et al.  Neuronal Nicotinic Receptors in Dementia with Lewy Bodies and Schizophrenia , 1999, Journal of neurochemistry.

[48]  K. Blennow,et al.  Decreased protein level of nicotinic receptor alpha7 subunit in the frontal cortex from schizophrenic brain. , 1999, Neuroreport.

[49]  J P Changeux,et al.  International Union of Pharmacology. XX. Current status of the nomenclature for nicotinic acetylcholine receptors and their subunits. , 1999, Pharmacological reviews.

[50]  B. Potter,et al.  Characterisation of the binding of [3H]methyllycaconitine: a new radioligand for labelling α7-type neuronal nicotinic acetylcholine receptors , 1999, Neuropharmacology.

[51]  Karl J. Friston,et al.  Human Brain Function , 1997 .

[52]  R. Freedman,et al.  Evidence in postmortem brain tissue for decreased numbers of hippocampal nicotinic receptors in schizophrenia , 1995, Biological Psychiatry.

[53]  S. Arneric,et al.  Nicotinic receptor binding of [3H]cytisine, [3H]nicotine and [3H]methylcarbamylcholine in rat brain. , 1994, European journal of pharmacology.

[54]  G. Pearlson,et al.  Positron emission tomography reveals elevated D2 dopamine receptors in drug-naive schizophrenics. , 1986, Science.

[55]  G. Sedvall,et al.  Quantitative analysis of D2 dopamine receptor binding in the living human brain by PET. , 1986, Science.

[56]  P. Davies,et al.  Postmortem stability of α-bungarotoxin binding sites in mouse and human brain , 1981, Brain Research.

[57]  D. Bertrand,et al.  Neuronal α7 Nicotinic Receptors as a Target for the Treatment of Schizophrenia. , 2015, International review of neurobiology.

[58]  Kenji Hashimoto,et al.  α7 nicotinic acetylcholine receptor as a potential therapeutic target for schizophrenia. , 2011, Current pharmaceutical design.

[59]  J. Mikkelsen,et al.  Cognitive improvement by activation of alpha7 nicotinic acetylcholine receptors: from animal models to human pathophysiology. , 2010, Current pharmaceutical design.

[60]  E. Albuquerque,et al.  Mammalian nicotinic acetylcholine receptors: from structure to function. , 2009, Physiological reviews.

[61]  R. Freedman,et al.  Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia. , 2006, Archives of general psychiatry.

[62]  Albert Gjedde,et al.  Mapping neuroreceptors at work: on the definition and interpretation of binding potentials after 20 years of progress. , 2005, International review of neurobiology.

[63]  R. Papke,et al.  Hydroxy metabolites of the Alzheimer's drug candidate 3-[(2,4-dimethoxy)benzylidene]-anabaseine dihydrochloride (GTS-21): their molecular properties, interactions with brain nicotinic receptors, and brain penetration. , 2004, Molecular pharmacology.

[64]  Nikos Makris,et al.  Automatically parcellating the human cerebral cortex. , 2004, Cerebral cortex.

[65]  R Freedman,et al.  Schizophrenia, sensory gating, and nicotinic receptors. , 1998, Schizophrenia bulletin.

[66]  P. Davies,et al.  Postmortem stability of alpha-bungarotoxin binding sites in mouse and human brain. , 1981, Brain research.

[67]  Derivatives of , 2022 .